United States marijuana legalization and opioid mortality epidemic during 2010–2020 and pandemic implications

The hypothesis that marijuana availability reduces opioid mortality merits more complete testing, especially in a country with the world’s highest opioid death rate and 2nd highest cannabis-use-disorder prevalence.

The United States opioid mortality rate was compared in states and District of Columbia that had implemented marijuana legalization with states that had not, by applying joinpoint methodology to Centers for Disease Control and Prevention data. Variables included race/ethnicity and fentanyl-type opioids (fentanyls).

After the same rates during 2010–2012, the opioid mortality rate increased more rapidly in marijuana-legalizing than non-legalizing jurisdictions (2010–2020 annual pairwise comparison p = 0.003 for all opioids and p = 0.0004 for fentanyls). During the past decade, all four major race/ethnicities in the U.S. had evidence for a statistically-significant greater increase in opioid mortality rates in legalizing than non-legalizing jurisdictions. Among legalizing jurisdictions, the greatest mortality rate increase for all opioids was in non-Hispanic blacks (27%/year, p = 0.0001) and for fentanyls in Hispanics (45%/year, p = 0.0000008). The greatest annual opioid mortality increase occurred in 2020, the first year of the COVID-19 pandemic, with non-Hispanic blacks having the greatest increase in legalizing vs. non-legalizing opioid-death-rate difference, from 32% higher in legalizing jurisdictions in 2019 to more than double in 2020.

Instead of supporting the marijuana protection hypothesis, ecologic associations at the national level suggest that marijuana legalization has contributed to the U.S.’s opioid epidemic in all major races/ethnicities, and especially in blacks. If so, the increased use of marijuana during the 2020–2022 pandemic may thereby worsen the country’s opioid crisis.


To read the full study by IASIC Board Member Kevin Flinn, click here: https://www.sciencedirect.com/science/article/abs/pii/S0027968422000529?dgcid=coauthor

For more information on the International Academy on the Science and Impact of Cannabis, and to join, please visit www.IASIC1.org.

Visit the IASIC Library here (https://iasic1.org/library/). The IASIC Library is intended as a user-friendly reference of the published medical literature.

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on pinterest
Share on Pinterest

Leave a comment

Related Posts

What is THCP?

THCP, which is short for tetrahydrocannabiphorol and scientifically known as (-)-Trans-Δ9-tetrahydrocannabiphorol, is a natural cannabinoid and analog of THC present in varieties of cannabis. It’s thought to be 33 times more active at cannabinoid 1 (CB1) receptors than THC, causing an intense and intoxicating euphoric high. THCP’s legality is stuck between conflicting federal legislation. It’s not

Cannabis Legalization and Detection of Tetrahydrocannabinol (THC) in Injured Drivers

A recent study funded by the Canadian Institutes of Health Research found that after cannabis legalization, the prevalence of moderately injured drivers with a THC level of at least 2 ng per milliliter in participating British Columbia trauma centers more than doubled. The increase was largest among older drivers and male drivers. During the study

Cannabis Contaminants Limit Pharmacological Use of Cannabidiol

For nearly a century, Cannabis has been stigmatized and criminalized across the globe, but in recent years, there has been a growing interest in Cannabis due to the therapeutic potential of phytocannabinoids. With this emerging interest in Cannabis, concerns have arisen about the possible contaminations of hemp with pesticides, heavy metals, microbial pathogens, and carcinogenic compounds during the cultivation, manufacturing,

Scroll to Top